News
Company News: Curetis Receives U.S. FDA De Novo Clearance of Unyvero System and Unyvero LRT Lower Respiratory Tract Infection Cartridge
– First ever multiplex MDx test to be granted clearance by the FDA for this indication
– Commercial launch in the U.S. expected this quarter
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, announced today that the Company has been granted a De Novo clearance by the U.S. Food and Drug Administration (FDA) to market the Unyvero System and Lower Respiratory Tract Infection (LRT) Application Cartridge in the U.S.
Company News: Curetis To Attend Key Investor and Scientific Conferences In The Second Quarter 2018
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that the Company is going to attend several industry conferences in the second quarter of 2018.
Company News: Project Group ProDetekt at Life Science Inkubator (LSI) Sachsen receives maximum patent protection in Europe for PRET-ELISA key technology
– Significant performance and efficiency improvement of ELISA-based protein analytics
Dresden, Germany, March 15, 2018 – ProDetekt, a start-up project incubated at Life Science Inkubator Sachsen, has been granted broad European patent protection for its novel PRET-ELISA technology supplementing the ELISA method used in bioanalytics world-wide. ELISA (Enzyme-linked Immunosorbent Assay) is being applied routinely in biomedical research and everyday clinical practice, e.g. to determine disease-relevant biomarkers in complex biological samples.
Company News: Curetis Receives USPTO Notice of Allowance for Key Patent Covering Unyvero Technology
— IP position strengthened in the U.S.
— Patent supports utility of Unyvero Lysator Technology for sample preparation
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it has received a notice of allowance from the United States Patent & Trademark Office (USPTO) for U.S. Patent Application 14/232,391 (“Apparatus and Method for a Lysis of a Sample, in Particular for an Automated and/or Controlled Lysis of a Sample”) covering its Unyvero Lysator patient sample preparation technology.